This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
Publication about the first ten years of clinical experience with decellularized homografts for pulmonary valve replacement / Patient inclusion to the ESPOIR clinical trial
Surgeons, cardiologists and pediatric cardiologists from Hannover Medical School/Germany and the University Hospital in Chisinau/Moldavia have published the clinical experience derived from ten years of clinical experience using... [more]
Patient inclusion on the increase for the ESPOIR clinical study
The ESPOIR study group, comprising 7 hospitals from Hannover, Chisinau, London, Leuven, Leiden, Padua, Zurich and 4 homograft banks from Brussels, Hannover, Treviso and Rotterdam, has now reached full operative capacity. This has... [more]
A decade of clinical experience with decellularized homografts presented at the 2015 EACTS
Researchers from Hannover Medical School, Germany and Universitatea Nicolae Testemitianu, Chisinau, Moldavia presented their clinical experience with fresh, non-cryopreserved, decellularized pulmonary homografts over the last ten... [more]
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.